LIVE DAY 2 ✦ September 24 - CT (Central Time)
LIVE DAY 2 ✦ September 24 - CT (Central Time)
- Odalys Caprisecca - Vice President, Managed Markets Finance, Novartis Pharmaceuticals Corporation
- Maria Ghazal - President & CEO, Healthcare Leadership Council
Insights on process for chosen drugs and timeline, portal challenges
What do we hypothesize the final MFPs signal about CMS discount justification?
What to prepare and best practices on process: Documentation and data
What types of drugs are higher risk for selection based on parameters
- Jesse Mendelsohn - Senior Vice President, Model N
- Sharon Small - Director, Counsel Market Access, Government Pricing & Policy, Novartis
- J'Amie Conrod, MSPH - Senior Director, Government Payor Engagement, U.S. Market Access, Amgen
- Dana Lerro - Healthcare Strategy and Policy Analytics, Market Access, BMS
How does your company decide to price a new product? How do you monitor the pricing lifecycle, deal with SPTR, mandatory discounts, WAC, caps? Not only is setting discounts year to year a challenge but thinking in terms of long rage impact is a growing concern with pricing becoming more restrained. What factors do you need to pay attention to in accordance with your exposure as a company?
Medicare and Medicaid changes in 2025 and beyond
Exposure in Medicare based on rebates
Payer reimbursement and payer management with continued pressure from payers
Contracting strategy based on downstream impacts to the industry introducing additional obligations to the government
What keeps YOU up at night? The newest requirements for State Drug Pricing? Is it the circling litigation with 340B and contract pharmacies? IRA and Medicaid negotiations? Smoothing and stacking? PBMs and PDABs? Join this open Q&A with external counsel to get answers to your most challenging questions. We’ll also hear about issues that keep them up at night and how it will impact you. *Pre-Conference we’ll poll the attendees for questions to ask our speakers.
- Odalys Caprisecca - Vice President, Managed Markets Finance, Novartis Pharmaceuticals Corporation
Information regarding all modifications made to rules, regulations, and calculations over the past year, along with their effects on product and delivery processes
Examine current litigation surrounding IRA
IRA rebates impact on accruals, forecasting, and new product launches - how to tailor product launch strategy with rebate accruals in mind
- Felecia Manning - Senior Director, Managed Markets Pricing & Government Programs, United Therapeutics Corporation
Navigating the complex pricing practices in the industry and pulling the curtain back on how the pricing was determined
Mapping out the operationalization of the IRA and how to prep for adjustments
If we are trailing the product from manufacturer to final customer, how do we account for those steps and verify the actions?
How do you approach “following the pill” across all channels while addressing all possible discounts?
Using the 10 products authorized, identify how the data was captured and possibilities for improvement upon the process
- Judd Caulfield - Lead Counsel, Oncology Business Unit, Takeda Pharmaceuticals
Pharma is in the crosshairs of society, media, and the government and there is perceived complication among the community concerning the Best Price Stacking Rule.
Dissect and elucidate the proposed regulation with intricate detail
Provide an overview of the burdens for all involved parties and understanding the push and pull of implementing the Best Price Stacking Rule
Identify solutions for operationalizing the proposed rule
- Lynn Buhl - Senior Director, Riparian
- Chris Weiser - Senior Corporate Counsel, US Market Access Legal, Sanofi
Current state of litigation on contract pharmacies by manufacturers
Genesis implications: What do court findings mean for the future of the program and manufacturer approaches?
340B confluence with IRA and state regulatory movements
Insights on policy on patient definition and eligibility
- John Gould - Partner, Arnold & Porter
How to incorporate policy assessments earlier in the development process
Working with global and R&D colleagues more closely to mitigate risks created by this program early on
Best resources for active, streamlined 340B validated customers list
Noncompliance with 340B program consequences
- Matthew Fornataro - Partner, Arnold & Porter
Change in contract pharmacy policy overview
State perceived gain from AMP cap removal dissected
Status of 340B growth and reform efforts
Federal and state level review of 340B legislation: Exploring the new bills
Dealing with continued 340B ramifications
States outlawing the identifiers for Medicaid and 340B
Struggling to reach a consensus with wholesalers on ID participation
Manufacturers sensing more difficulty interfacing with states on duplicate discounts
- Marcella Lynch - Director, Forecasting and Pricing - Market Access, Rare Diseases, Chiesi USA, Inc.
Pharma perspective on internally evaluating contracts and work stream using AI and predictive analytics
Resulting learnings, tips and tricks
Interactive Q&A
Case study on how to successfully utilize advanced AI for duplicate discount data scrubbing in the biosimilar and ultra rare space
Leverage AI for data validation and forecasting
Interfacing with states with the most receptivity possible on duplicate discounts
- Tom Evegan - Principal, Strategy & Management Consulting, RSM US LLP
Guardrails for incorporating AI
Most beneficial areas where AI can be deployed: pricing, data scrubbing, forecasting future liability, Medicaid claims, membership, etc.
Future creative capabilities exposed
- Mitesh Ghia - Director, Institutional Contracts, Chargebacks & Rebates, Novartis Pharmaceuticals Corporations
Join this anonymous live polling session to reveal bot competencies, uses, challenges, creation processes and more!
Are you using homegrown bots or from a vendor?
What capabilities do you look for?
What setbacks have you had?
Wishlist for future automation?
- Tracy Zheng - Senior Market Access Operations Director, Exelixis